Hypofractionated Radiotherapy Noninferior for High-Risk Breast Cancer PMRT

This phase III randomized trial compared hypofractionated (42.56 Gy/16 fractions) versus conventionally fractionated (50 Gy/25 fractions) postmastectomy radiotherapy including internal mammary node irradiation in 1,429 patients with high-risk, operable breast cancer. The trial reported that 5-year locoregional recurrence was noninferior with hypofractionation (1.7% vs 2.2%), with no significant differences in distant metastasis-free survival, disease-free survival, or overall survival, while grade 3 acute skin toxicity was significantly lower with the hypofractionated regimen (1.7% vs 12.2%) and cardiopulmonary toxicity was low and comparable between arms.

Most relevant for: Patients with high-risk, operable breast cancer requiring postmastectomy radiotherapy with internal mammary node irradiation.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.